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Objectives. This study examiaed the toa@em~ ~.montb) ef. 
I& of nebivdol, a r~ew bcta~adrcneqto MoekIng sgcnt, on 
cardtac Derrommnce in Pattents with ditnkd rpnlh?mYM&b”. 
Several beta-adrenergic blocking drugs have been reporled 
(l-7) to have beneficial effecrs in patients with dilated cardic- 
myopathy. In a recent double.blInd comuarison of the nonse- 
l&e bdtablocking agent buciodolol wiih placebo, Gilten et 
rd. (6) observed a beneficial effect on hemodynamic variables 
and ejection fraction after 3 months of treatment. They dem- 
onstrated in a subseauent studv ln that the beneficial effect . 
was maintained for 2 years. However, they could not deter- 
mine the mechanism for improved performance (that is, 
whether it was due to the nonadrenoceptor.m. Sated wso. 
dilating effects of the drug or : direct myocardial effect of 
aamk results were obtained in thr catb+terkatioa taboratory. 
Analysis Mhigb WeMy measumwnln of kft veatrkdar pmzauc 
ineadqstdkshaa.Tl&aetrt&rssrd@&atirrarcia 
electkm f& 1-r lwm 0.23 to 0.33 n. 0.21 to 0.23 wftb 
long4enn beta.blockadel. In an elegBnl bU1 uaonlrollcd study 
of buciodolol on myoeardii performance, Eiihbom et al. (5) 
concluded that after 3 months of therapy, improved perfw 
mallcc was the result of an improvemat in myocaidii con- 
traclility without an increaSe in myocardiat oxygen demand. 
Taken together. these studies suggest that long-term 
treatment with a beta-blocking drug with vasodilating prop 
erties may improve cardiac performance lhrough a para- 
doxic improvement in czmtractility. However, because of 
the reluctance of many practitioners IO initiate a potentially 
deleterious form of treatment in patients with cardiomyopa- 
thy, we thoughf ic worlhwhile to combine the separale 
strengths of these two studies in a comprehcosive invcsliga- 
tion of the new beta-blocking agent (RSSS + SRRR)- 
liminobis(methylene~lbis16_Ruorc-3,4-ZH-l-~naopy~n~2~ 
methaooll-HCCnebivoloCin &ems with cardiomvooathv. 
Nebivoloi is a mcemic mixt& of two eoandm&: ihe 12 
isomer is a longacting beti~~-adrenergk antagonist that, al- 
though more uotem and more beta,-s&dive in vitro, has 
a hemodynamic profile qualitatively resembling that of 
atenolol(8): the nonbeta-blocking Gamer, io contrast to both 
o-nebivolol and atenolol, decreases peripheral resistance after 
intravenous injection in dogs by at unexplained mech&w 
that does not appear to be mediated by any kooown receptor 
(9). Bacemic nebivolol also reduces oaioheral resistance in 
humans after oral adminisuation attd’a n&tinvasive index of 
left ventricular performance is improved (10). Nebivdol has 
little if any alpha-adrenetgic antagonistic effects (IO) and is 
devoid of intrinsic sympathcmimetic activity (II). 
Our pmtocol was randomized, double-blind and included 
exercise testing, measurement of plasma biochemical vari- 
ables, including catecholamines at baseline attd after 3 months, 
24-h invasive hemodyoamic monitoring and invasive as- 
~essntent of I& ventricular wall stress and contractility in an 
attempt to separate the effects of load and conttactility on 
ptfomtance. 
Methods 
Sludy de+. The protocol was approved by the Ethics 
Committee of the University of Witwatersnnd and Bang- 
wmath Hospital. After an explanation of the protocol in his 
or her own language, each patient gave informed amsent 
before study enhy. The study war double-blind. randomized 
and placebo-controlled with two parallel arms. Randomization 
block size was four. The placebo ruwin phase wa I month and 
the randomized pb~ was 12 weeks. Twelve patients were 
initially randomized to each gmup. However. four patients 
randot&& to nebiidd therapy failed to complete the pm@ 
cd: one died, two were withdrawn because of newly diagnosed 
or worsening diabetes mellitus and one defaulted fw social 
reasons. The latter three patients. who either were withdrawn 
w defaulted, were repl&ed by an additional three patients 
withat the randomized tratment b&w divutped to the inves- 
tigators. Thus, II patients in the neb&lol &I completed the 
pmtwxi. Cl&e patient in the placebo group defaulted for social 
reasons. This patient was inadvellentiy rephced with 2 pa- 
tients: thus, 13 patients completed the placebo arm of the 
study. Hemodynamic assessment petformed at the end of the 
nut-in phase included 12 h of hewdynamic monitoring with 
Swan-Ganz catheters before radomiration and. at 4 h after 
placebo administration. I& heart cathetetization with left ven- 
tticular cineangiography. The 24-h hemaiytwic study and 
attgiqmphic assessment were repeated at the end of the 
randomized phase. Two exercise tests (modified Naugbton 
pmtocd) were petfomted during the nut-in phase at weekly 
intervals, again weekly during the Meek titration phase, at 
week 6 and ftnally at comple%n of the trial. 
Rtkmt sckctim. Eligibility criteria were I) age ~18 and 
~6.5 years, 2) stable New York Heart Associa!ion functional 
class II oc III congestive heart failure an diuretic therapy 
fl&osemide). 31 svstolic left ventricular dvsfunction (eiec- 
iionfraetio~~.~5 tb0.4Obygated radionucli&angiogra&L 
4) abiiity to perform treadmill exercise for a4 and 512 min 
using a modiied Nau&ton protocol, and 5) reproducible 
6 
0.2s f 0.08 
exercise perfotmance during a t-month placebo run-in phase 
(that is, two successive exercise durations within 2 mitt 
pafomted at weekly intervals). Exclusion criteria were 
I) chmnic obstructive puhwwy disease, 2) sign&ant val- 
vular heart disease. 3) diioiic blond pressure >I05 mm Hg, 
3) myocatdial ititian or stroke within the past 6 months, 
4) insulin-dependent diabetes. 5) creatiniwe >2.2 m&U, 6) liver 
disease defined as enq-ws more than twice the upper lit of 
nom-li, il wwn of child-healing potential, 8) symptomatic 
~ythmiaswauial6~,9)useoldigonin,~ensin- 
converting inhiitors or other beta-blocm drugs, 8) weight 
>tS% of ideal weight, and 9) alcohol &use. 
Characteristics of the patients enrolled are shown in 
Table 1. Cornnary angiagraphy revealed severe tw* and 
three-vessel disease sunmestive of an ischemic ori& in two 
patients (nebivolol Gp) and minor (GO% n&rowing) 
disease in four others (three in the nebivolol group and one 
in the olacelm aowL No other soecific etiolties for heart 
failure were id~nti&d and. an the basis of the exclusion 
criteria, no patient was thought to have a predomioantly 
hypertensive origin of heart failure. All patients were native 
Africans. 
hup titaim. After the ha@& hemodynamic study, pa- 
tients were randomized to receive nebivolol (I @day) or 
placebo. The drug dose was increased at weekly intervals over 
the next 2 weeks to 2.5 and 5 mg if well tolerated. AU patients 
were maintained on fimsemide plus pMassium supplementa- 
tion. 
Hemcdyxmmic and angi~apbic stud&es. Twelve-hour 
monitoring with Swa&anz catheters was performed hourly 
at the end of the run-in phase and for 24 h again (hourly for 
12 hand then once every 3 h for 12 h) at the completion of 
the trial. TO ensure stability, catheters were inserted though 
the subclavian or jugular vein on the evening before the 
monitoring period began; patients fasted during this time. 
Pulmonary wedge pressure and cardiac output measure- 
moots were repeated until ~10% variation was observed 
between two consecutive meas”rements before drugs were 
administered. During the baseline study, left heart catheter- 
ization with left ventricular tine- and conmar, angiography 
were performed 4 h after hemodynamic monitoring was 
initiated and placebo was given because this is the time 
estimated to reach peak effect for nebivolol. During the final 
period of hemodynamic monitoring, left heart satheteriza- 
tion and I& ventricular cineangiography were again per- 
formed at 4 h after drug (nebivolol or placebo) was given. 
The femoral armroach with local anesthesia onlv was used. 
Left ventt’icul~~ pressure was measured with & 8F micro- 
manometer pigtail catheter. Biplane left ventricular cinean- 
glography was performed with 40 to 50 ml of sodium 
meglumine ioxaglate. 
Methods used for analysis of the left ventricular pressure 
aad simultaneous angiographic volume data, and estimation 
of contractile function using the preload-corrected ejection 
fraction (EE!-end svstolic stress (ES9 relations have been 
described ihdetail (i2). The p&ndic&r distance of data 
for each individual patient from the previous1y published 
regression line of a normal control group (12) was comwted 
as: PESS x sine(arctangent[regression slope]), where hESS 
is the horizontal distance from the preload.corrected ejec- 
tion fraction-end-systolic stress coordinate to the regression 
line. This is a modification of the method of Lang et al. (13), 
who used the vertical distance at a common end-systolic 
stress. Diastolic pressure-volume data were not considered 
adequate for estimation of preload-corrected ejection 
fraction in one patient in the nebivolol group and in one 
patient in the placebo group at baseline study and another 
at 3 months. All angiographic analyses were performed 
in a blinded fashion before the drug codes wew broken. 
Pressure-volume loops were con&ted from digitized 
micromanometer left ventricular oressore (not smoothed) 
and from frame by frame angiographic (area-length) volomb 
time data smoothed with a 10th.order polynomial equation 
using a Marquardt curve-fitting program. 
5iocbemicl studies. Plasma norepincphrine analysis was 
performed by using high performance liquid chromatogra- 
phy; blood samples were immediately put on ice after they 
were drawn. Routine biochemistry studies were performed 
with standard technique. 
.Stat&s. Two-way analysis of variance was used to assess 
ditTerent responses between the nebivolol and placebo groups. 
Drugdosinga~~I&Iee&ts~ Themaximaldoseofdmgwas 
reachedin7oFlIpatientsrandomLedtonebivololand llof13 
randomized to placeb+ therapy. Medication compliaoce deter- 
mined by pill cwnt was >% in all but two patients (85% 
e~nplianeebyeaeh)inthenebivddgmupand>%inallbut 
one patient (7% compliance) in the placebo group. 
Two patients initially randomized to nebivolol were with- 
drawn before completion of the protocol because of new or 
worsening diabetes (see Methods). There was one sudden 
death in the mhivolol group. Of the II patients who com- 
pleted the nebivolol arm of the protocol. one complained of 
mental depression but did not have to be withdrawn fmm the 
study. In the remaining patients, side etiect protiles were 
low. with no admissions for worsening heart failure. 
Exe&e time. There was no signii?cant change in ever- 
cise duration in either group, nor was there any difference 
between the groups at baseline (554 + 70 s at baseline to 
536 f 83 s at 3 months for the mbivolol group sod 492 + 
I21 s to 570 + 105 8 for the placebo group). Peak systolic 
blood pressure in the nebivolol groop was I50 1 24 mm Hg 
at baseline aad 145 + 22 mm Hg at 3 months (p = NS): 
maximal heart rate was 140 + 12 beatslmin at baseline and 
decreased to I20 f 22 beatdmin at 5 months (p = 0.005). In 
the placebo gmup, the correspandiog exercise vuiabies were 
160+19mmHgvel3us158~25mmHgat3monulsand 
143 * 22 beats/min to 147 f 21 bcatslmin @ = NS for both). 
Hnnodrpunka (Tabk 2, Fii. 1). Twelve- and 24-h inva- 
sive monitoring showed that only heart rate and stroke 
volume were sigailicantly altered by aebivolol; decreases in 
systemic &stance. systemic arterial pressure. wedge pres- 
Tab+ 1. Elects of Nehivolol Versus Placebo on 12. and 24%~ Swan.Ganz Measurement of Hcmodynamic VariaMcs 
Nebivolol Placebo p Value foi EUat of 
Before After B&c After w GWP 
Figure I. Percent change fmm baseline to mean arterial pressure 
WAP). sys:emic vascular esistance (SK+), hext mte (Hal. puI- 
monary caapillarv wedge Pre*swe tKW and thenmxtitutiun rtmks 
volume (SW a&r 3 months of nebivolol or placebo administration. 
sow and pulmonary artery pressure were not significantly 
differcat from those in the placebo group. The only hemo- 
dynamic deterioration in the oebivolol group was as follows: 
one patient bad a sigoiiicant decline (defined as a 20% 
decrease fmm the baseline value) in cardiac output without 
a significant chaoge in wedge pressure, and one patient had 
a sigoificant increase in wedge pressure without a significant 
change in cardii output. Neither of these patients had to be 
withdrawn from the study because of side effects. Similar 
mcasurcments were obtained for both groups in the cathe- 
terization laboratorv ITable 3). Analvsis of hieh lid&v 
measurements of lek &ic& p&are in the”ttebivol~l 
group showed a denease in IeR ventricular end-diastolic 
prcssurc but no change in the maximal rate of prcssttre 
development (dP/dt_) or in either measured variable of 
left venttictdar relaxation (maximal negative first derivative 
of left ventricular pressure [-dP/dt_l or time constant 
IW). 
Artgiographll data flMk4, fig. 2). Despite adccrcase in 
heart rate with nebivolol, there was a sliabt decrease in left 
ventricular enddias!olic volume (p = 6): left venrriculw 
mass was also decreased at 3 months compared with the 
baseline mra~uremeot (p = 0.01). End-systdic u&m-c dc- 
creased even though there was no sigaifieant decline in 
afterload measured eitbw as systemic vascular resistatw or 
end-systolic stress. The net result was a sigairicant increase 
in ejection fraction, presumably due to an increasc in myo. 
cardial contractibty. This finding was corroborated by an 
increase in the relation of prcload-corrected ejection fraction 
(EF,) to end-systolic strcs (Fig. 3). An exam& of a 
pressure-volume loop before and 3 months after iebivolol 
administration is shown io Fiure 4. The reoroducibilitv of 
the angiographic data is supp&ed by the c&c corrclaiion 
between left ventricular rcass al baseline and at 3 mooths in 
the placebo group (Fig. 5). 
Biibcmiml data. Despite high dose dixctic tttempy 
(mean dose of urosemide at baseline and 3 months I60 and 
176 mg in the nebivdol group and 178 and 200 mg in the 
placebo group. respectively), blood urea and creatinine did 
not increase and there were no chaws in scntm potassium. 
sodium or mttgnesium. Flasma twepittcphtiae levels tended 
to decrease in the ttebivolol group (819 2 M to 5% r 
419 pmol!liter) and IO itw-case in the placebo gmap (555 i 
376 to 972 .? 271 pawHiter). but the difference was not 
statistically significant. 
Di8m88ion 
Comparison with pwiom &dies. Ooe previous study (5) 
has shown that long-term beta-blockade may improve herno- 
dynamics (l-7) in cardiomyopathy throw& a long-term in- 
crease in myoeardial contractility. This is ao intriguing 
Table 4. Elects of Nebivolol Versus Pl~ceho on Left Ventricular Volume and Stress 
posribili(y because the short-term administration of beta- 
blockers produces a negative inotropic effecl. Although that 
study included elegant measurement of ventricular perfor- 
mance (E,,.), it was not placebo controlled. Recatw of our 
interest in confirming such a mechanism of action in a 
placebo-controlled study and because of the reluctance of 
many to use a potentially deleterious therapy in patients with 
heart failure. the present detailed investigation was per- 
formed. Our results confim, those of Eichhom et al. (5). who 
showed that hemodynamic improvement oec”rs through a” 
improvement in contractile perforntanee and not simply 
because of a change in heart rate or loading conditions. 
Several strengths in our study design lend credibility to 
this seemingly paradoxic conclusion that long-term treat- 
ment with a beta-blocker improves depressed contractility in 
cardiomyopa:hy. First, the addition of a placebo control 
group ensures that improvement in the treatment group was 
not spontaneous, as may occur with some types of cardio- 
myopathy (14): Hemodynamic status and left ventricular 
size and function were remarkably stable over the 3.mo”th 
Figure 1. Percent change from baseline in end-diastolic volume 
(ED0 end-systolic volume (ESV), ejecdon fraction (EF). left 
ventricular mass index (LVMI) and left ventricular end.diaotolic 
pressure (LVEDP) after 3 months of nebivolol or placebo adminis- 
tration. 
period of placebo administration in this group, with no 
significant change in diuretic dose. Second, the immediate 
measurements obtained in the catheterization laboratory 
wcrc corroborated by 12-h (at baseline) and 24-h (at j 
months) monitoring. This observation is critical because 
Rcker et al. (15) have show” that hemodynamic stems can 
change dramatically during the early period of monitoring 
etIer catheter insertion. Third. our patients were all stabi- 
lized on diuretic therapy alone, whereas in the study of 
Eichhorn et al. (S), all medications-including, presumably, 
positive isotropic agents such as digoxin and vasodilators 
such as angiotensiwwnvening enzyme inhibitor+were al- 
lowed. These medicalions were also allowed in the impor- 
tant studies of Gilbert et al. (6) and Anderson et at. (7). 
Finally, both bocindolol and nebivolol are thought to have 
vasodilating progenies and we considered it importam to 
assess long-term druge6ects on end-systolic stress to ensure 
that improvement in ejection fraction war not a result of 
reduced wall stress. The similarity of baseline and 3-month 
end-systolic stress in both treatment arms of our study 
stren&“s lhis condasio” and wmbomtes otu estimate df 
contractiliw 112). which is otherwise own to criticism. 
Contrrchk & i~*utlw h?em. it is noteworthy tbal 
in 19 of 22 patients with cardiomyopathy in the present 
rludv. the oreload-corrected eieclion fractio”-end-systolic 
st&relaiibn, our index of co&actile function, was~below 
the 95% prediction band defined by a previously studied (12) 
contmi group. This finding sumests that our index is indeed 
gnsitive lo chronically depressed contractile state, and it 
has previously been shown to be relatively load independent 
(12): Although we could not detect a”; increase in peak 
positive dl’ldt, this index of contractility decreases with 
decreasing preload (16). and the decrease in preload ob- 
served in OUT patients may have been responsible for “egat- 
ing the expected increase in peak positive dP/dt. 
In contrast to the study of bucindolol of Eichhom et al. 
(5). we were not able to demonstrate any improvement in 
variables of mvofardial relaxation (“oak neeative dP/dt and 
the time constant mu). Whether this diiTerence betweeo 
studies is due to a difference in drug properties or simply a 
methodologic difference is not apparent. Nevertheless, 
Flguw 3. A, Contmtility ertimated as pretuad-corrected ejection 
fraction (EFJ versus &dead (end-systolic stress [ESSll before 
and afier nebivold. There is a marked shitl reward the normal 
regression line by a nriln of tO.12 unit (from -0.36 i 0.13 to 
-0.24 + 0. IS et 3 months) for the IO patients in whom adequate data 
were avaikbk. 8. Nochange inertknted contractility &the placebo 
group Ithal is, the mean prpendicular distance te the EF,-ESS 
regrersien tine [-0.29 f 0.14 to -029 2 0.14 unit at 3 monthsjj. 
nebivolol signilicantly reduced lefi ventricular end-diastolic 
pressure, presumably as a result of the improvement in 
systolic performance. 
Exercke tderanee. Exercise tolerance did not improve 
with treatment, an e&t that may in part be due to the 
20.beat/rein decrease in maximal heat? rate with nebivolol. 
In the few previous studies of beta-blockade for cardiomy- 
opathy, the effect cm exercise tolerance has differed. Curie 
et al. (17) found no improvement in filling pressure or 
exercise tolerance and a decrease in maximill heart rate of 32 
beats/mitt after 1 month of treatment with metoprolol. In a 
recent study of bucindolol by Gilbert et al. (6). exercise 
tolerance did not improve despite improvements in both 
Volume (ml) 
Figure 4. Prcssursvv~u~~~e Imps before @axtine) and atIer (Final) 
nrbivotol administration. demenstrrdinga marked reduction ofbeth 
end-diastolic and end-systolic v&me without a deerease in pw 
sure. PI = vatient. 
hsmodynamics and IeR ventricular function; maxiwd heart 
rate was also significantly decreased by treatment. In con- 
trast. Engelmeier et al. (18) observed an improvement in 
exercise time with metopmlnl and no signilicent reduction in 
maximal heart rate. Other factors contributing to impaired 
exercise tolemttce in patients treated for cardiomy&tby 
include ahnormalities in exercising skeletal muscle (19) and 
direct effects of beta-blockade on skeletal muscle perfor- 
mance (20). 
Figure 5. Placebo gmup. Regression line relating an&graphic I& 
ventricular mass index (LVMI) at baseline (wdieate) and 3 months 
(sbsriw) is near identity. 
Mechanisms. The mechanism by which long-term beta- 
blockade improves myocardial contractility is unknown. The 
work of Eichhom et al. (5) suggests that improved ntyocar- 
dial energetics may play a role. It is also possible that 
beta-blockade reduces the toxic effects (21) of high cat* 
cholamine levels (22) on the myacardium. Increased beta- 
receptor density has also been proposed (23). but it is 
unclear how this would improve contractility ifthe receptors 
are pharmacologically blocked. 
Drug safety. Long-term treatment with phosphodiester- 
ase inhibitors, which have a short-term positive inotropic 
effect, is poorly tolerated and increases the incidence of 
death (24). In contrast, beta-blockade given in gradually 
increasing doses has been well tolerated in patients with 
cardiomyopathy and, in the few previous studies that in- 
cluded a control group (6.7,18), no deaths were attributable 
to treatment. There was one death in the nebivolol arm ofthe 
present study. Ischemia or a malignant arrhythmia, or both, 
probably accounted for this sudden death and, in v!c’u of the 
results of the Beta-Blocker Heart Attack Trial (2% it is 
wlikely that treatment with nebivolol played a causal role. 
Larger studies are needed to confirm the role of beta- 
blockade in reducing malignant arrhythmias and mortality in 
patients with dilated cardiomyopathy (3). 
Llmitallons of the study. First, the small size ofthis study 
probably prevented us from documenting more significant 
improvement in hemodynamic variables. Second, estimation 
of contractile performance is a limitation with the present or 
any other index of contractility. However, an increase in 
ejection fraction despite a reduction in preload (end-diastolic 
pressure and volume) and no change in afte+xtd (end- 
systolic stress) is difficult to exolain bv any mechanism other 
than an increase in contm~tile~perfo~man. 
Conclusions. Nebivolol is well tolerated with few side 
effects in patients with cardiomyopathy who are in stable 
condition and who are on high dose diuretic therapy. With 
longterm treatment, the drug has a negative chronotropic 
effect hut paradoxically a positive inotropic effect, which 
results in a favorable hemodynamic response with an in- 
crease in stroke volume and a reduction in left ventriadar 
filling pressure. Finally, despite hemodynamic improve- 
ment. exercise tolerance does not improve. 
We arc grateful for the technral assistance of Ana Shaw. NDCT and Rieky 
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